KRAS Wild-Type, EGFR Expressing mCRC
Review efficacy results from tumor-location subgroup post hoc analyses of 3 phase III trials in RAS wild-type mCRC
See the CRYSTAL, FIRE-3, and CALGB/SWOG 80405 trials
CRYSTAL=Cetuximab combined with iRinotecan in first-line therapY for metaSTatic colorectAL cancer
CRYSTAL regimen=cetuximab with FOLFIRI
FIRE-3: FOLFIRI + cetuximab versus FOLFIRI + bevacizumab as first-line treatment for patients with mCRC
CALGB=Cancer and Leukemia Group B; SWOG=Southwest Oncology Group.
Please see CRYSTAL study design following the efficacy results below